HTDS - Hard to Treat Diseases (PINK)

[Jerico]

aka - Pump & Dumps

HTDS was being promoted by a known "Stock Promoter" as disclosed by their website:
"Hard to Treat Diseases : The LLC Companies received $15,000 and 50,000,000 free trading shares from a non-affiliate third party shareholder and thereafter sold all 50,000,000 shares."
OTCReporter.com :: Disclaimer

They were 'outed' in this article:

The Street Sweeper - Convicted Swindler Touts Risky Penny Stocks

[olivervaldivia]

What you guys think about HTDS ?

i think it will have a good run. i got in at .0009

Multiple Paths for Success (PINK:HTDS) |

i was waiting

[bdogsdad]

Not much difference between this guy and Mina Mar..

[shockdragon]

Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals
---------------------------------------------------------------------------
Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals

BEIJING, CHINA, Feb. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) brings attention to a certain previously released news announcements namely January 7 2009, November 19, 2009, Dec 15, 2009 January 12,2010, and January 22, 2010.

These are significant dates and important events for the company as all of these events are now starting to crystallize and are beginning to transform HTDS from a Vaccine and a RD company to a much more diversified company encompassing several health care and cosmetics sectors. Firstly, In a certain news release dated Jan 7, 2009 - HTDS announced its desire to expand into the cosmetics field. Shortly thereafter HTDS acquired interest in a micro cosmetics company in East Europe. The cosmetics company Melem Secrets is engaged in online sales of the "Melem" product. Over the past 12 months, this division of HTDS slowly and while under the radar, continued developing contacts, networking, and doing business; while adding various new products and services. Shortly the company intends to unveil its new web site together with a launch of its cosmetic services. A new CEO of the cosmetics division only is planned including additional sales, and administrative staff. Shortly thereafter this division will start releasing its progresses made, contracts, and revenues. HTDS shareholders and followers by all accounts should pleasantly be surprised.

With the January 22, 2010 news release, the company entertained an unsolicited business proposal from an obstetrician type medical company. This Middle East Company is engaged in a treatment of pre-term labor and induction of labor. These symptoms affect millions of people worldwide. The company is pleased to report that it is in final short strokes of its negotiations with this targeted company. Details will be released shortly.

The company's Slavica Bio Chem division remains undisturbed. Slavica medical research activities include neurophysiologists, and molecular biologists working on neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI).

At the core of HTDS business is the China based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of Biological Vaccines in China. Based on the cooperation with Institutes of Medical Biology and Pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy. The company brings attention to a certain news release of Dec 15, 2009 and November 19, 2009 titled - "Hard To Treat Diseases (HTDS) Chilean first order of 200,000 doses". Significant progress on the aforementioned Chilean order has been achieved by HTDS. The company is hopeful that the details could be made available within the 1st Quarter of 2010.

In other news and events the company is in receipt of the 40 million shares from HIRU representing the sale of HTDS MindUp division. See link http://www.pinksheets.com/otciq/ajax...d.pdf?id=28354 or see filing filling by HIRU with Pink Sheets dated January 29, 2010 Labeled Hiru Acquires Mind Up from Hard to Treat Diseases.

The Jan. 12 2010 news release is self explanatory. - Hard to Treat Diseases, Inc. (HTDS; announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.

Subsequently a 5-1 forward split was announced by HIRU which will affect HTDS for a distribution of about 200 million shares versus the original 40 million to our shareholders.

Moving forward assuming all of the above comes to fruition HTDS will have 4 unique and distinct operating subsidiaries in the health care and cosmetics - beauty aid sector. A source close to the company was asked if this configuration will remain permanent in HTDS? "The company will do whatever is in the best interest of the company and its shareholders. Nothing is written in stone. Should a suitable buyer come along at the right price and terms, everything is open for discussion. Right now there is no buyer in the wings or nothing in the works or on the horizon having just completed the sale of the MindUp project. We are disheartened that the governing or self regulatory bodies simply choose to do nothing and what appears to us chose to side with short sellers and "over sellers" instead of at least remaining neutral. We are pleased to see some of the stock bashers rained in with the recent court ruling which in its sense gave us our second wind, and the will to come back with a vengeance. The company remains committed to restore values as evidenced by the strides it made so far. The slow stream of news announcements in January and February 2010 (compared to the recent past) can best be defined as "the HTDS calm before the storm". I know that HTDS management continues to have aspirations of completing its audit and delivering on all promises made to its long term shareholders and followers. The best of HTDS is yet to come."

To be included in HTDS' email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: Mina Mar Group.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiries only, please contact medicalinfo@htdsmedical.com; for any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

[bdogsdad]

Time will tell but I don't have much confidence in HTDS for the near future anyhow.. The next big mover will be Q4 IMO, it had better be good or this puppy is gone.. GLTA..

[rajkranti]

Hopefully it will go up soon.

[bdogsdad]

Maybe but I don't think so. Not this year anyway..

[shockdragon]

SHENZHEN, China, Feb. 18 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) and its China subsidiary Mellow Hope announce that the company exported the first lot of H1N1 Vaccine to Chile.

Mellow Hope exported the first shipment of H1N1 vaccine to Chile. The company values order to about $1 million USD. The company endured a lengthy regulatory approval for the H1N1 vaccine's export, but since the company established the export channel, HTDS doesn't expect any further setbacks with H1N1 vaccine exports to Chile.

HTDS' CEO Terry Yuan said, "We encountered some routine complications with getting the shipping and import permits in order. These complications stalled our effort to ship our H1N1 vaccine ASAP. It's all taken care of now, we opened the channels and can schedule routine shipments of our H1N1 vaccine for Chile. This contract has been in the works for months. We were expecting to have shipped this order back in November - December 2009 however it took several additional months to clear all legal and administrative hurdles. In a medical industry this is the norm. We work hard to get our orders filled and secure more contracts with other countries, from which we've received previous inquiries about our H1N1 vaccine. Gaining government permissions often stretches, but that doesn't stop our success, or determination."

In other company news HTDS recently launched its new Melem Secrets cosmetics web site Melem Secret. A new CEO of that division will shortly be announced together with some of the impressive progresses made to date. HTDS brings attention to the January 22, 2010 news release. This is an unsolicited merger proposal from an obstetrician type medical company. This Middle East Company is engaged in a treatment of pre-term labor and induction of labor. Both companies are fine tuning the details and working out the logistics. More updates and details of the targeted merger will be released shortly.

Moving forward, HTDS management foresees 4 unique and distinct operating subsidiaries operating under the HTDS umbrella in the health care and cosmetics - beauty aid sector.

The company reminds our shareholders and followers to monitor PinkSheets.Com Filing Section and also our IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link Mina Mar Marketing Group - Kayako SupportSuite Help Desk Software for further updates on this and other business matters. Non-newsworthy events are not press released however posted on these two separate support sites to keep our followers advised of day-to-day events. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support Section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, MinaMarGroup - International financial consulting firm and reverse merger transaction specialists.

SOURCE Hard to Treat Diseases

Hard To Treat Diseases (HTDS) Ships First $1 Million USD Order to Chile

[bdogsdad]

Got a little pop outta that one, hope it continues today..

[shockdragon]

BEIJING, CHINA, Feb. 25 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) - Further to the previously announced cosmetics merger (press release Feb 5, 2010) negotiations with the cosmetic company Melem Secrets, and other business matters the company is pleased to report that it has completed a cosmetic micro-conglomerate merger.

Collagenna Skin Care Products Inc (Collagenna) is a thriving micro cosmetics company. Collagenna briefly ventured into the public markets in 2009 and subsequently rescinded that merger upon learning that the parent company at that time had certain undisclosed legal issues. Collagenna will manage Melem Secrets and use Melem as a direct marketing company for all Collagenna product lines.

A source close to HTDS' said, "We see new and innovative products of Collagenna's as a great asset for our long anticipated expansion into cosmetic field. These companies may not show a stunning market value at the present, however revenues in the $500,000 range and projected to reach 3 million in the next 8 to 10 quarters is considered quite aggressive in any economy. Collagenna did pull its own weight and did quite good as a public company in 2009 HTDS management believes that they have great prospects for the future."

Collagenna was acquired on all cash basis therefore the existing share structure of HTDS will remain undisturbed and unchanged.

In other company news the company is continuing its research and assessment of the regenerative medicine and the stem cell bank projects. Additional information will be released as it becomes available. The company has been made aware of certain rumors circulating in the investment community that its insiders are selling their position or will sell their position in March 2010. This is untrue. All insider sales are strictly governed by SEC Rule 144 and to date no such act has taken place nor are there any plans for this in March of 2010 or in the foreseeable future.

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link Mina Mar Marketing Group - Kayako SupportSuite Help Desk Software should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Hard to Treat Diseases (HTDS) Melem Secrets' Completes Merger